Resources

U.S. biomanufacturing is scaling fast. Faster, in fact, than most organizations are built to handle under regulatory scrutiny. U.S. biomanufacturing pledged investment since 2024, with pharmaceutical and life sciences companies pledging upwards

Biopharma leaders are being asked to do something that is directionally clear but operationally complex: Reshore manufacturing, reduce dependency on overseas production, and strengthen supply chain resilience. That pressure is coming from